Want to see CH:DOCM full AI Analyst Report?
DOCM Stock Chart & Stats
CHF6.61
CHF0.36(1.86%)
At close: 4:00 PM EST
CHF6.61
CHF0.36(1.86%)
Day’s Range― - ―
52-Week RangeCHF3.92 - CHF11.25
Previous CloseN/A
Volume45.75K
Average Volume (3M)342.18K
Market Cap
CHF521.08M
Enterprise ValueCHF276.63
Total Cash (Recent Filing)CHF149.92M
Total Debt (Recent Filing)CHF288.64M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.60
Shares Outstanding52,400,000
10 Day Avg. Volume377,518
30 Day Avg. Volume342,178
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.75
Price to Sales (P/S)0.27
P/FCF Ratio-3.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF9.93Price Target Upside50.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.74
Revenue Forecast (FY)CHF1.23B
Bulls Say, Bears Say
Bulls Say
High-margin Digital ServicesDigital Services grew 110% and are described as high‑margin contributors that drive the majority of CM3. This durable revenue mix shift toward high take‑rate services supports structural margin expansion, higher incremental profit per customer, and accelerates a sustainable path to EBITDA and FCF breakeven.
Large Platform ScaleAn ~11m customer base, increasing repeat rates and higher AOV create durable network and customer‑lifecycle advantages. Scale lowers marginal CAC, enables meaningful cross‑sell between Rx/OTC and digital services, and supports steady revenue retention that underpins medium‑term growth and profitability targets.
Improved Liquidity & LeverageMaterial liquidity (CHF160m), lower net debt and a ~50% equity ratio materially improve financial flexibility versus prior years. This provides multi‑quarter runway to execute margin and working‑capital fixes, reducing immediate refinancing urgency while pursuing 2026 EBITDA and 2027 FCF breakeven targets.
Bears Say
Persistent Cash BurnOperating and free cash flows deteriorated materially in 2025, driving deep negative cash generation. Persistent cash burn forces reliance on external funding or asset measures if operational improvement is delayed, constraining investments, limiting strategic optionality and raising refinancing risk over the medium term.
Ongoing LossesRecurring net losses and volatile earnings indicate the core retail pharmacy economics remain challenged. Negative margins erode equity returns and require sustained operational progress to convert revenue growth into durable profitability; otherwise capital allocation and reinvestment will remain constrained.
Logistics & Working Capital StrainManagement highlighted logistics cost pressure and material working‑capital inefficiencies (overstocking and receivables). These operational shortcomings compress margins and increase cash requirements; fixing them is necessary for durable margin recovery and to prevent recurring cash outflows that impair the path to breakeven.
DOCM FAQ
What was DocMorris AG’s price range in the past 12 months?
DocMorris AG lowest stock price was CHF3.92 and its highest was CHF11.25 in the past 12 months.
What is DocMorris AG’s market cap?
DocMorris AG’s market cap is CHF521.08M.
When is DocMorris AG’s upcoming earnings report date?
DocMorris AG’s upcoming earnings report date is Aug 19, 2026 which is in 29 days.
How were DocMorris AG’s earnings last quarter?
Currently, no data Available
Is DocMorris AG overvalued?
According to Wall Street analysts DocMorris AG’s price is currently Undervalued.
Does DocMorris AG pay dividends?
DocMorris AG does not currently pay dividends.
What is DocMorris AG’s EPS estimate?
DocMorris AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does DocMorris AG have?
DocMorris AG has 52,400,000 shares outstanding.
What happened to DocMorris AG’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of DocMorris AG?
Currently, no hedge funds are holding shares in CH:DOCM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
DocMorris AG
DocMorris AG is a key player in the pharmaceutical sector, focusing on both online pharmacy services and the wholesale supply of medical and pharmaceutical goods. The company provides a comprehensive selection of items, including prescription and over-the-counter medications, health and wellness products, beauty and personal care lines, dietary supplements, pain relief remedies, and emergency first aid supplies. Furthermore, it offers specialized medication management support. In addition to its significant digital footprint, DocMorris AG also operates traditional brick-and-mortar pharmacy locations. Its commercial activities extend across Switzerland and into various international territories, serving medical practitioners, other online pharmaceutical distributors, and individual consumers directly. Notable brands within its portfolio include Zur Rose, PromoFarma, TeleClinic, and DocMorris. Established in 1993 and based in Frauenfeld, Switzerland, the company adopted its current name, DocMorris AG, in May 2023, having previously been known as Zur Rose Group AG.
DOCM Stock 12 Month Forecast
Average Price Target
CHF9.93
▲(50.15% Upside)
Technical Analysis
Idorsia Ltd
―
Santhera Pharmaceuticals Holding
―
Galenica AG
―
Galderma Group AG
―
medmix AG
―